REGENXBIO Inc. (RGNX) News
Filter RGNX News Items
RGNX News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
RGNX News Highlights
- RGNX's 30 day story count now stands at 2.
- Over the past 23 days, the trend for RGNX's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
Latest RGNX News From Around the Web
Below are the latest news stories about REGENXBIO INC that investors may wish to consider to help them evaluate RGNX as an investment opportunity.
Regenxbio Inc President and CEO Kenneth Mills Sells 45,000 SharesKenneth Mills, President and CEO of Regenxbio Inc (NASDAQ:RGNX), executed a sale of 45,000 shares in the company on December 19, 2023, according to a recent SEC Filing. |
REGENXBIO Announces Dose Escalation in AFFINITY DUCHENNE® TrialREGENXBIO Inc. (Nasdaq: RGNX) today announced that the first patient received RGX-202 at dose level 2 in the Phase I/II AFFINITY DUCHENNE® trial. RGX-202 is an investigational one-time AAV Therapeutic for Duchenne muscular dystrophy (Duchenne), using the NAV® AAV8 vector to deliver a transgene for a novel microdystrophin that includes the functional elements of the C-Terminal (CT) domain as well as a muscle-specific promoter to support a targeted therapy for improved resistance to muscle damage |
Wall Street Analysts Believe Regenxbio (RGNX) Could Rally 95.61%: Here's is How to TradeThe average of price targets set by Wall Street analysts indicates a potential upside of 95.6% in Regenxbio (RGNX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock. |
REGENXBIO (NASDAQ:RGNX) adds US$111m to market cap in the past 7 days, though investors from five years ago are still down 72%REGENXBIO Inc. ( NASDAQ:RGNX ) shareholders should be happy to see the share price up 16% in the last week. But will... |
REGENXBIO Inc. (NASDAQ:RGNX) Q3 2023 Earnings Call TranscriptREGENXBIO Inc. (NASDAQ:RGNX) Q3 2023 Earnings Call Transcript November 8, 2023 REGENXBIO Inc. beats earnings expectations. Reported EPS is $-1.41, expectations were $-1.44. Operator: Good day, and thank you for standing by. Welcome to REGENXBIO’s Third Quarter 2023 Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speakers’ presentation, […] |
REGENXBIO Announces Updated Strategic Plans and Third Quarter 2023 Financial ResultsREGENXBIO Inc. (Nasdaq: RGNX) today announced financial results for the third quarter ended September 30, 2023, and recent operational highlights, including a strategic pipeline prioritization and corporate restructuring intended to significantly reduce operating expenses while continuing to support meaningful value generation from the Company's strong pipeline of AAV Therapeutics. |
REGENXBIO to Participate in Upcoming Investor ConferencesREGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate the following upcoming investor conferences: |
REGENXBIO Presents Positive One Year Data from Phase II ALTITUDE® Trial of ABBV-RGX-314 for Treatment of Diabetic Retinopathy Using Suprachoroidal DeliveryREGENXBIO Inc. (Nasdaq: RGNX) today announced additional positive data from the ongoing Phase II ALTITUDE® trial of ABBV-RGX-314 for the treatment of diabetic retinopathy (DR) without center-involved diabetic macular edema (CI-DME) using in-office suprachoroidal delivery. The data will be presented at the American Academy of Ophthalmology meeting in San Francisco, CA by Mark Barakat, M.D., Retinal Consultants of Arizona. ABBV-RGX-314 is being investigated as a potential one-time gene therapy for |
REGENXBIO to Host Conference Call on November 8 to Discuss Third Quarter 2023 Financial Results and Recent Operational HighlightsREGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host a conference call on Wednesday, November 8, 2023, at 4:30 p.m. EST to discuss its financial results for the quarter ended September 30, 2023, and recent operational highlights. |
REGENXBIO Announces Presentations at the American Academy of Ophthalmology 2023 Annual MeetingREGENXBIO Inc. (Nasdaq: RGNX) today announced presentations at the American Academy of Ophthalmology (AAO) 2023 Annual Meeting being held November 3-6, 2023 in San Francisco, CA. The presentations will highlight new data for ABBV-RGX-314, an investigational one-time AAV Therapeutic being developed in collaboration with AbbVie for the treatment of wet age-related macular degeneration (wet AMD), diabetic retinopathy (DR) and other additional chronic retinal conditions. |